B超,CT与DSA对肝癌介入治疗的指导价值

对１２６列原发性肝癌与３７例转移性肝癌介入治疗前均进行了Ｂ超、ＣＴ与数字减影血管造影（ＤＳＡ）检查。ＤＳＡ显示原发性肝癌多数血供丰富，而转移性肝癌以少血供者为主；ＣＴ显示小病灶的敏感性稍差，病灶的密度和均匀性与血供多少有一定关系，但特异性不高，而病灶的增强次应与血供关系密切，多血供者中９５％有显示的增强效应，少血供者仅占４．７％；Ｂ超所示病灶的回声高低与血供亦有一定关系，但特异性稍差。结果表明，Ｄ     

小鼠原位脂肪肝移植模型的建立

目的　建立了ob/ob小鼠脂肪肝移植模型 ,探讨保证建模成功的关键因素。方法　采用小鼠非动脉化肝移植技术 ,5～ 7周肥胖小鼠为供体 ,正常小鼠为受体 ,双袖套法行原位肝移植。受体肝组织行HE染色和油红O染色 ,血清ALT、AST水平检测采用常规生化分析法。结果非脂肪肝移植组 (lean to lean)受体长期存活率 (n =10 )为 70 % ,脂肪肝移植组 (ob/obtoagematchedlean)受体存活率为 0 (n =10 ) ,差异有显著性 (P <0 .0 5 )。脂肪肝移植给体积相当的正常小鼠 ,其短期存活率为 3 0 % (n =10 ) ,所有小鼠术后存活并苏醒 ,但均未超过 2 4h。脂肪肝移植受体ALT水平为 (62 85± 2 93 7)U /L ,AST为 (5 812± 2 942 )U /L ;而正常小鼠移植组ALT与AST水平分别为 (5 96± 114 )U /L ,(1796± 870 )U/L ,差异有显著性 (P <0 .0 5 ) ,组织学检测显示大量胆管中央凝固性坏死伴出血。结论　该模型的成功建立为我们提供了一种新的肝原发性肝无功能移植模型 ,为脂肪肝移植后脂肪肝细胞受损的机制研究奠定了基础。     

肝腺瘤的影像学诊断

目的探讨影像学(US、CT、MRI及DSA)诊断肝腺瘤的价值。方法回顾性分析经手术、病理证实的11例肝腺瘤的影像学表现,其中11例行US和CT检查(有1例行CT灌注成像,CTP),5例行MRI扫描,4例行DSA检查,并与手术病理所见对照。结果11例肝腺瘤均为单发肿块,无肝硬化背景,直径2.0～10.0cm。影像学表现:US检查,10例呈稍低或不均匀稍强回声,边界清晰,6例见低回声晕,彩色多普勒显示肿块内有较丰富的血流;CT检查,10例为稍低或等密度,8/10例动脉期全瘤明显强化,门脉期轻度强化,延迟期呈等密度,1例平扫和延迟期呈等密度,动脉期中度强化,门脉期轻度强化,误诊为血管瘤。1/11例CT灌注成像(CTP)检查,肝动脉灌注量(HAP)=1.08ml/(min.ml),门静脉灌注量(PVP)=0.19ml/(min.ml),肝动脉灌注指数(HPI)=0.85,各参数值与肝癌均有明显不同;MRI检查,5例肝腺瘤均能显示完整包膜,T1WI上2例稍高于肝脏信号,1例呈等信号,2例为稍低信号,T2WI上5例均表现为以稍高信号为主的混杂信号,脂肪抑制像(STIR)1例呈略低信号,4例信号与T2WI相似,行增强扫描的4例病灶动脉期显著强化,门脉期强化减退,平衡期呈等信号。DSA检查,3/4例病灶见粗细不均的异常血管影,实质期可见肿瘤染色表现。结论肝腺瘤的US和DSA表现均缺乏特异性,CT、MRI则具有一定的特点。CTP对肝腺瘤可能具有诊断和鉴别诊断价值。     

肝内胆管细胞癌的CT表现

目的分析胆管细胞癌的CT表现,提高对胆管细胞癌的认识。方法回顾性分析经病理证实的21例胆管细胞癌的CT表现。结果CT平扫所有病例均为单发低密度灶。CT增强扫描21例不均匀轻度强化,其中4例出现大片无强化低密度区,部分边缘强化,2例病灶延迟强化,17例肝内胆管扩张。结论CT是胆管细胞癌的重要影像检查方法,不均匀强化病灶内可见胆管扩张是胆管细胞癌的重要征象。     

2型糖尿病并脂肪肝与血脂紊乱的关系探讨

目的　探讨 2型糖尿病并脂肪肝患者与脂代谢紊乱之间的关系。方法　对 60例 2型糖尿病并脂肪肝和 5 2例 2型糖尿病不并有脂肪肝病例的血脂谱 ,空腹血糖 (FPG ) ,餐后 2小时血糖 ( 2hPG) ,空腹胰岛素 (FINS)进行测定 ,计算体重指数 (BMI)及胰岛素敏感指数 (ISI)。结果　 2型糖尿病并脂肪肝与不并脂肪肝相比 ,甘油三脂 (TG) ,低密度脂蛋白胆固醇 (LDL -C) ,FINS均升高 (P <0 .0 5 ,P <0 .0 1) ,而ISI明显降低 (P <0 .0 1)、脂蛋白a(Lp(a)降低(P <0 .0 5 )。结论　 2型糖尿病并脂肪肝比不并脂肪肝者存在明显脂代谢紊乱及胰岛素抵抗     

脂必妥胶囊联合疏肝祛瘀中药治疗脂肪肝的临床观察

[目的]探讨脂必妥胶囊联合疏肝健脾、化痰祛瘀中药治疗脂肪肝的临床疗效。[方法]将45例脂肪肝患者随机分为两组,治疗组25例,使用脂必妥胶囊联合疏肝健脾、化痰祛瘀中药治疗3月;对照组20例,单用脂必妥胶囊治疗3月,观察患者治疗前后血清丙氨酸转氨酶（ALT）、甘油三酯（TG）、血清总胆固醇（TC）的变化。[结果]治疗组总有效率为84.0%,而对照组仅70.0%;治疗组TG、TC治疗后下降明显;治疗后与对照组治疗后比较也下降明显。[结论]脂必妥胶囊联合疏肝健脾、化痰祛瘀中药治疗脂肪肝是一种有效的方法。     

Update on ascites and hepatorenal syndrome

Ascites is the most common complication occurring during liver cirrhosis. Even if a significant decrease in renal clearance may be observed in the first step of chronic active liver disease, renal impairment, at times complicated by the typical signs of hepatorenal syndrome, occurs only in patients with ascites, especially when tense and refractory. Experimental and clinical data seem to suggest a primary sodium and water retention in the pathogenesis of ascites, in the presence of an intrahepatic increase of hydrostatic pressure, which, by itself, physiologically occurs during digestion. Abnormal sodium and water handling leads to plasma volume expansion, followed by decreased peripheral vascular resistance and increased cardiac output. This second step is in agreement with the peripheral arterial vasodilation hypothesis, depicted by an increase in total blood volume, but with a decreased effective arterial blood volume. This discrepancy leads to the activation of the sympathetic nervous and renin-angiotensin-aldosterone systems associated with the progressive activation of the renal autacoid systems, especially, that of the arachidonic acid. During advanced cirrhosis, renal impairment becomes more sustained and renal autacoid vasodilating substances are less available, possibly due to a progressive exhaustion of these systems. At the same time ascites becomes refractory inasmuch as it is no longer responsive to diuretic treatment. Various pathogenetic mechanisms leading to refractory ascites are mentioned. Finally, several treatment approaches to overcome the reduced effectiveness of diuretic therapy are cited. Paracentesis, together with simultaneous administration of human albumin or other plasma expanders is the main common approach to treat refractory ascites and to avoid a further decrease in renal failure. Other effective tools are: administration of terlipressin together with albumin, implantation of the Le Veen shunt, surgical porto-systemic shunting or transjugular intrahepatic portosystemic stent-shunt, or orthotopic liver transplantation, according to the conditions of the individual patient.     

Effect of cirrhosis and renal failure on the kinetics of clotiazepam

Summary The kinetics of a single 5-mg oral dose of the thienodiazepine clotiazepam was evaluated in a series of patients with biopsy-proven cirrhosis, and in patients with renal insufficiency requiring maintenance hemodialysis, compared to healthy matched controls. Clotiazepam volume of distribution (V_z) was significantly smaller in cirrhotic patients than in controls (1.83 vs 2.57 l/kg), and total clearance was likewise reduced (2.15 vs 3.15 ml/min/kg). Elimination half-life was similar between groups (10.0 vs. 10.2h). There were no significant differences between renal failure and control patients in clotiazepam V_z, oral clearance, or elimination half-life. Thus cirrhosis is associated with reduced clearance of clotiazepam, probably due to impairment of its microsomal oxidation. However clotiazepam disposition is not significantly altered in dialysis-dependent renal insufficiency patients.Supported in part by Grant OC 10/6–4 from Deutsche Forschungsgemeinschaft, and Grant MH-34223 from the United States Public Health Service.     

Enhancement of hepatic hemangiomas with levovist on coded harmonic angiographic ultrasonography.

OBJECTIVE: To evaluate the pattern of contrast enhancement with Levovist on coded harmonic angiographic ultrasonography of hepatic hemangiomas. METHODS: Twenty hemangiomas were evaluated with coded harmonic angiographic ultrasonography and a microbubble contrast agent. Verification of the diagnosis of a hemangioma was made by means of dynamic computed tomography (n = 8), dynamic magnetic resonance imaging (n = 1), radionuclide scanning (n = 6), or follow-up ultrasonography (n = 5). Ultrasonographic images were obtained before contrast agent administration and with a bolus injection of 2.5 g of a microbubble contrast agent (300 mg/mL Levovist; Schering AG, Berlin, Germany) every 10 to 15 seconds for 5 minutes. The contrast enhancement patterns of the 20 hemangiomas were assessed. RESULTS: The tumor diameters as measured on ultrasonography were 7 to 97 mm (mean, 26.7 mm). Of the 20 hemangiomas, peripheral globular enhancement with progressive centripetal fill-in was shown in 15 (75%), rimlike enhancement with progressive centripetal fill-in was shown in 2 (10%), and homogeneous enhancement was shown in 1 (5%). In the remaining 2 lesions (10%), the enhancement patterns could not be seen, because they were not found on coded harmonic angiographic ultrasonography. CONCLUSIONS: Coded harmonic angiographic ultrasonography with a microbubble contrast agent can depict the typical enhancement pattern in most hepatic hemangiomas.     

慢性肝病和肝癌中HCV核心区三种寡肽抗原的抗体检测

检测１４８例慢性肝病和肝癌患者血清中丙型肝炎病毒核心区３种寡肽抗原的抗体，结果显示其阳性率在慢性迁延型肝炎、慢性活动型肝炎、肝炎肝硬化和原发性肝癌患者分别为７．７％，２３．１％，，２３．５％和１６．３％。在抗体阳性者中８０％以上有乙型肝炎病毒感染证据，提示我国ＨＢＶ和ＨＶＣ重叠感染较为常见。